EMA Spells Out Dos and Don’ts Of Developing Drugs For Elderly
The European Medicines Agency has outlined various factors that companies should consider when developing medicines for older patients, who are at the highest risk of encountering usability problems when taking medicines.
You may also be interested in...
The European Medicines Agency has explained how companies developing medicines for older people can better address the needs of this patient population.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.